Efficacy of combined therapy in patients with hepatitis B virus-related decompensated cirrhosis

Table 1 Baseline characteristics of patients with hepatitis B virus-related decompensated cirrhosis (mean ± SD)

Characteristics	De novo combination group (n = 70)	Lamivudine group (n = 70)	P value
Age (yr)	46.8 ± 10.3	47.1 ± 10.9	0.91
Male/female	41/29	40/30	0.89
ALT (IU/L)	134.6 ± 101.3	132.4 ± 120.8	0.78
TBIL (μmol/L)	38.5 ± 12.1	37.8 ± 11.9	0.84
Albumin (g/dL)	3.2 ± 0.7	3.3 ± 0.6 0.34
Prothrombin time (s)	17.1 ± 4.5	17.6 ± 3.1	0.61
HBV DNA (log10 copies/mL)	6.87 ± 1.21	6.94 ± 1.15	0.73
HBeAg positive	34 (48.6)	33 (47.1)	0.94
Platelet count (× 109/L)	78.9 ± 24.2	76.7 ± 32.3	0.67
Creatinine (μmol/L)	89.7 ± 12.3	88.6 ± 13.1	0.45
GFR (mL/min)	115.2 ± 34.5	113.5 ± 22.9	0.68
CTP score	8.9 ± 2.1	8.8 ± 1.7	0.83
CTP class
A	6 (8.6)	7 (10)	0.65
B	48 (68.6)	49 (70)	0.77
C	16 (22.9)	14 (20)	0.59
MELD score	12.4 ± 3.7	11.9 ± 2.5	0.75

ALT: Alanine aminotransferase; TBIL: Total bilirubin; GFR: Glomerular filtration rate; HBV: Hepatitis B virus; HBeAg: Hepatitis B e antigen; CTP: Child-Turcotte-Pugh score; MELD: Model for End-Stage Liver Disease.